Regulation of Nlrp3 inflammasome by dietary metabolites

Seminars in Immunology

Volumn 27, Issue 5, 2015, Pages 334-342

  Camell, Christina ^a   Goldberg, Emily ^a   Dixit, Vishwa Deep ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAMP; Dietary intervention; Fatty acids; Ketones; Macrophage; Metabolite; Nlrp3 inflammasome; Sterile inflammation

Indexed keywords

CRYOPYRIN; DAMAGE ASSOCIATED MOLECULAR PATTERN PROTEIN; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; INFLAMMASOME; INTERLEUKIN 1; KETONE; OMEGA 3 FATTY ACID; PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CALORIC RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME REGULATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; GOUT; HUMAN; INFLAMMATORY DISEASE; KETOGENESIS; MACROPHAGE; METABOLIC DISORDER; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; PATHOGENESIS; POLARIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DIET; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; METABOLIC DISEASES; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; DIET; ENERGY METABOLISM; HUMANS; IMMUNOMODULATION; INFLAMMASOMES; INFLAMMATION; MACROPHAGES; METABOLIC DISEASES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION;

EID: 84952876142     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.10.004     Document Type: Review

References (107)

1. Wen H., Miao E.A., Ting J.P. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013, 39:432-441.
2. Lamkanfi M., Dixit V.M. Mechanisms and functions of inflammasomes. Cell 2014, 157:1013-1022.
3. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
4. Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Current Biology 2004, 14:1929-1934.
5. Man S.M., Kanneganti T.D. Regulation of inflammasome activation. Immunological Reviews 2015, 265:6-21.
6. Miao E.A., Leaf I.A., Treuting P.M., Mao D.P., Dors M., Sarkar A., et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nature Immunology 2010, 11:1136-1142.
7. Mankan A.K., Dau T., Jenne D., Hornung V. The NLRP3/ASC/Caspase-1 axis regulates IL-1beta processing in neutrophils. European Journal of Immunology 2012, 42:710-715.
8. Karmakar M., Katsnelson M., Malak H.A., Greene N.G., Howell S.J., Hise A.G., et al. Neutrophil IL-1beta processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. Journal of Immunology 2015, 194:1763-1775.
9. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nature Reviews. Immunology 2010, 10:89-102.
10. Isoda K., Sawada S., Ishigami N., Matsuki T., Miyazaki K., Kusuhara M., et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:1068-1073.
11. Merhi-Soussi F., Kwak B.R., Magne D., Chadjichristos C., Berti M., Pelli G., et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovascular Research 2005, 66:583-593.
12. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine 2000, 191:313-320.
13. Y.S. Lee, H. Yang, J.Y. Yang, Y. Kim, S.H. Lee, J.H. Kim, et al., Interleukin-1 signaling in intestinal stromal cells controls KC/CXCR1 secretion, which correlates with the recruitment of IL-22-secreting neutrophils at early stages of Citrobacter rodentium infection, Infection and Immunity (2015).
14. Calkins C.M., Bensard D.D., Shames B.D., Pulido E.J., Abraham E., Fernandez N., et al. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. Journal of Endotoxin Research 2002, 8:59-67.
15. Ben-Sasson S.Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7119-7124.
16. Basu R., Whitley S.K., Bhaumik S., Zindl C.L., Schoeb T.R., Benveniste E.N., et al. IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. Nature Immunology 2015, 16:286-295.
17. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Research & Therapy 2007, 9:R28.
18. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine 2007, 356:1517-1526.
19. Munoz-Planillo R., Kuffa P., Martinez-Colon G., Smith B.L., Rajendiran T.M., Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38:1142-1153.
20. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nature Immunology 2013, 14:812-820.
21. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology 2008, 9:847-856.
22. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology 2010, 11:136-140.
23. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
24. Vats D., Mukundan L., Odegaard J.I., Zhang L., Smith K.L., Morel C.R., et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metabolism 2006, 4:13-24.
25. Xue J., Schmidt S.V., Sander J., Draffehn A., Krebs W., Quester I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.
26. Ji Y., Sun S., Xia S., Yang L., Li X., Qi L. Short term high fat diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin-4. The Journal of Biological Chemistry 2012, 287:24378-24386.
27. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
28. W.R. Bolus, D.A. Gutierrez, A.J. Kennedy, E.K. Anderson-Baucum, A.H. Hasty, CCR2 deficiency leads to increased eosinophils, alternative macrophage activation, and type 2 cytokine expression in adipose tissue, Journal of Leukocyte Biology (2015).
29. Molofsky A.B., Nussbaum J.C., Liang H.E., Van Dyken S.J., Cheng L.E., Mohapatra A., et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. The Journal of Experimental Medicine 2013, 210:535-549.
30. Kratz M., Coats B.R., Hisert K.B., Hagman D., Mutskov V., Peris E., et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metabolism 2014, 20:614-625.
31. Camell C., Smith C.W. Dietary oleic acid increases m2 macrophages in the mesenteric adipose tissue. PLoS One 2013, 8:e75147.
32. Kolodin D., van Panhuys N., Li C., Magnuson A.M., Cipolletta D., Miller C.M., et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metabolism 2015, 21:543-557.
33. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 2009, 15:930-939.
34. Odegaard J.I., Chawla A. Alternative macrophage activation and metabolism. Annual Review of Pathology 2011, 6:275-297.
35. Cipolletta D., Feuerer M., Li A., Kamei N., Lee J., Shoelson S.E., et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
36. Sekimoto R., Fukuda S., Maeda N., Tsushima Y., Matsuda K., Mori T., et al. Visualized macrophage dynamics and significance of S100A8 in obese fat. Proceedings of the National Academy of Sciences of the United States of America 2015, 112:E2058-E2066.
37. Erridge C., Attina T., Spickett C.M., Webb D.J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. The American Journal of Clinical Nutrition 2007, 86:1286-1292.
38. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 2009, 15:914-920.
39. Strissel K.J., DeFuria J., Shaul M.E., Bennett G., Greenberg A.S., Obin M.S. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity 2010, 18:1918-1925.
40. Amano S.U., Cohen J.L., Vangala P., Tencerova M., Nicoloro S.M., Yawe J.C., et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metabolism 2014, 19:162-171.
41. Oh D.Y., Morinaga H., Talukdar S., Bae E.J., Olefsky J.M. Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012, 61:346-354.
42. Kosteli A., Sugaru E., Haemmerle G., Martin J.F., Lei J., Zechner R., et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. The Journal of Clinical Investigation 2010, 120:3466-3479.
43. Lee Y.H., Petkova A.P., Granneman J.G. Identification of an adipogenic niche for adipose tissue remodeling and restoration. Cell Metabolism 2013, 18:355-367.
44. Ganeshan K., Chawla A. Metabolic regulation of immune responses. Annual Review of Immunology 2014, 32:609-634.
45. Newsholme P., Gordon S., Newsholme E.A. Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. The Biochemical Journal. 1987, 242:631-636.
46. Tan Z., Xie N., Cui H., Moellering D.R., Abraham E., Thannickal V.J., et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. Journal of Immunology 2015, 194:6082-6089.
47. Takahashi M., Yagyu H., Tazoe F., Nagashima S., Ohshiro T., Okada K., et al. Macrophage lipoprotein lipase modulates the development of atherosclerosis but not adiposity. Journal of Lipid Research 2013, 54:1124-1134.
48. Aouadi M., Vangala P., Yawe J.C., Tencerova M., Nicoloro S.M., Cohen J.L., et al. Lipid storage by adipose tissue macrophages regulates systemic glucose tolerance. American Journal of Physiology Endocrinology and Metabolism 2014, 307:E374-E383.
49. Huang S.C., Everts B., Ivanova Y., O'Sullivan D., Nascimento M., Smith A.M., et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nature Immunology 2014, 15:846-855.
50. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism 2005, 1:107-119.
51. Ding L., Biswas S., Morton R.E., Smith J.D., Hay N., Byzova T.V., et al. Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. Cell Metabolism 2012, 15:861-872.
52. Nicholls H.T., Kowalski G., Kennedy D.J., Risis S., Zaffino L.A., Watson N., et al. Hematopoietic cell-restricted deletion of CD36 reduces high-fat diet-induced macrophage infiltration and improves insulin signaling in adipose tissue. Diabetes 2011, 60:1100-1110.
53. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 2005, 11:90-94.
54. Yan Y., Jiang W., Spinetti T., Tardivel A., Castillo R., Bourquin C., et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013, 38:1154-1163.
55. Wang J., Wu X., Simonavicius N., Tian H., Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. The Journal of Biological Chemistry 2006, 281:34457-34464.
56. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
57. Namgaladze D., Lips S., Leiker T.J., Murphy R.C., Ekroos K., Ferreiros N., et al. Inhibition of macrophage fatty acid beta-oxidation exacerbates palmitate-induced inflammatory and endoplasmic reticulum stress responses. Diabetologia 2014, 57:1067-1077.
58. Malandrino M.I., Fucho R., Weber M., Calderon-Dominguez M., Mir J.F., Valcarcel L., et al. Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. American Journal of Physiology Endocrinology and Metabolism 2015, 308:E756-E769.
59. Ikonen E., Cellular cholesterol trafficking compartmentalization. Nature Reviews. Molecular Cell Biology 2008, 9:125-138.
60. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nature Reviews. Immunology 2013, 13:709-721.
61. Grevengoed T.J., Klett E.L., Coleman R.A. Acyl-CoA metabolism and partitioning. Annual Review of Nutrition. 2014, 34:1-30.
62. Gault C.R., Obeid L.M., Hannun Y.A. An overview of sphingolipid metabolism: from synthesis to breakdown. Advances in Experimental Medicine and Biology 2010, 688:1-23.
63. Xia J.Y., Morley T.S., Scherer P.E. The adipokine/ceramide axis: key aspects of insulin sensitization. Biochimie 2014, 96:130-139.
64. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Medicine 2011, 17:179-188.
65. Schilling J.D., Machkovech H.M., He L., Sidhu R., Fujiwara H., Weber K., et al. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. The Journal of Biological Chemistry 2013, 288:2923-2932.
66. Ussher J.R., Koves T.R., Cadete V.J., Zhang L., Jaswal J.S., Swyrd S.J., et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010, 59:2453-2464.
67. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metabolism 2007, 5:167-179.
68. Chakraborty M., Lou C., Huan C., Kuo M.S., Park T.S., Cao G., et al. Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosis. The Journal of Clinical Investigation 2013, 123:1784-1797.
69. Shah C., Yang G., Lee I., Bielawski J., Hannun Y.A., Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. The Journal of Biological Chemistry 2008, 283:13538-13548.
70. Mitsutake S., Date T., Yokota H., Sugiura M., Kohama T., Igarashi Y. Ceramide kinase deficiency improves diet-induced obesity and insulin resistance. FEBS Letters 2012, 586:1300-1305.
71. Wang J., Badeanlou L., Bielawski J., Ciaraldi T.P., Samad F. Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. American Journal of Physiology Endocrinology and Metabolism 2014, 306:E756-E768.
72. Xia J., Holland W.L., Kuminski C., Sun K., Sharma A., Pearson M., et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metabolism 2015, 22:1-13.
73. Turpin S.M., Nicholls H.T., Willmes D.M., Mourier A., Brodesser S., Wunderlich C.M., et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metabolism 2014, 20:678-686.
74. Kuhn H., Banthiya S., van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochimica et Biophysica Acta 2015, 1851:308-330.
75. Stables M.J., Gilroy D.W. Old and new generation lipid mediators in acute inflammation and resolution. Progress in Lipid Research 2011, 50:35-51.
76. Amaral F.A., Costa V.V., Tavares L.D., Sachs D., Coelho F.M., Fagundes C.T., et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis and Rheumatism 2012, 64:474-484.
77. Qiu H., Gabrielsen A., Agardh H.E., Wan M., Wetterholm A., Wong C.H., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8161-8166.
78. Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013, 496:238-242.
79. Moon J.S., Lee S., Park M.A., Siempos I.I., Haslip M., Lee P.J., et al. UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. The Journal of Clinical Investigation 2015, 125:665-680.
80. Koliwad S.K., Streeper R.S., Monetti M., Cornelissen I., Chan L., Terayama K., et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. The Journal of Clinical Investigation 2010, 120:756-767.
81. Chan J.M., Rimm E.B., Colditz G.A., Stampfer M.J., Willett W.C. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994, 17:961-969.
82. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nature Reviews. Immunology 2011, 11:98-107.
83. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunology 2011, 12:408-415.
84. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007, 148:241-251.
85. Youm Y.H., Adijiang A., Vandanmagsar B., Burk D., Ravussin A., Dixit V.D. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011, 152:4039-4045.
86. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:15324-15329.
87. WHO, Global Status Report on Noncommunicable Diseases, WHO Press, 2014.
88. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
89. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. The Journal of Biological Chemistry 2002, 277:38517-38523.
90. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nature Immunology 2010, 11:155-161.
91. Y. Zhu, B.J. Pandya, H.K. Choi, Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008, The American Journal of Medicine 125 (2012) 679-687.e671.
92. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis and Rheumatism 2011, 63:3136-3141.
93. Mitroulis I., Kambas K., Ritis K. Neutrophils, IL-1beta, and gout: is there a link?. Seminars in Immunopathology 2013, 35:501-512.
94. Holzinger D., Nippe N., Vogl T., Marketon K., Mysore V., Weinhage T., et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis & Rheumatology 2014, 66:1327-1339.
95. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
96. Omodei D., Fontana L. Calorie restriction and prevention of age-associated chronic disease. FEBS Letters 2011, 585:1537-1542.
97. E. Ravussin, L.M. Redman, J. Rochon, S.K. Das, L. Fontana, W.E. Kraus, et al., A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity, The Journals of Gerontology Series A, Biological Sciences and Medical Sciences (2015).
98. Coll R.C., Robertson A.A., Chae J.J., Higgins S.C., Munoz-Planillo R., Inserra M.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 2015, 21:248-255.
99. Lamkanfi M., Mueller J.L., Vitari A.C., Misaghi S., Fedorova A., Deshayes K., et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal of Cell Biology 2009, 187:61-70.
100. L'Homme L., Esser N., Riva L., Scheen A., Paquot N., Piette J., et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. Journal of Lipid Research 2013, 54:2998-3008.
101. Bjermo H., Iggman D., Kullberg J., Dahlman I., Johansson L., Persson L., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. The American Journal of Clinical Nutrition 2012, 95:1003-1012.
102. Lee T.C., Ivester P., Hester A.G., Sergeant S., Case L.D., Morgan T., et al. The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population. Lipids in Health and Disease 2014, 13:196.
103. Fukao T., Lopaschuk G.D., Mitchell G.A. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004, 70:243-251.
104. Halestrap A.P., Wilson M.C. The monocarboxylate transporter family-role and regulation. IUBMB Life 2012, 64:109-119.
105. Tan Z., Xie N., Banerjee S., Cui H., Fu M., Thannickal V.J., et al. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. The Journal of Biological Chemistry 2015, 290:46-55.
106. Rahman M., Muhammad S., Khan M.A., Chen H., Ridder D.A., Muller-Fielitz H., et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nature Communications 2014, 5:3944.
107. Youm Y.H., Nguyen K.Y., Grant R.W., Goldberg E.L., Bodogai M., Kim D., et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine 2015, 21:263-269.